/

Società

Me

Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

248 comunicati stampa

Guarda tutti i comunicati

29/10/2026

Veterinaria

HIV, AIDS e malattie autoimmuni

Igiene alimentare

Medicina - Varie

Cardiologia

Biotecnologia

Salute

Farmaceutica

Oncologia

Web e Social Network

Telefonia e Varie

Mercato azionario

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

Fonte

Merck & Co., Inc.

Emittente

1.00

0

26/10/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Industria

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Fonte

Merck & Co., Inc.

Emittente

1.00

0

26/10/2026

Oncologia

Salute

Igiene alimentare

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Eventi

Fiere

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

Fonte

Merck & Co., Inc.

Emittente

1.00

0

22/10/2026

Scienza

Medicina - Varie

Sanità

Biotecnologia

Farmaceutica

Salute

Oncologia

Eventi

Industria

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

Fonte

Merck & Co., Inc.

Emittente

1.00

0

21/10/2026

Oncologia

Salute

Medicina - Varie

Farmaceutica

Cardiologia

Biotecnologia

Industria

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

13/10/2026

Biotecnologia

Sanità

Farmaceutica

Salute

Mercato del lavoro

Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors

Fonte

Merck & Co., Inc.

Emittente

1.00

0

13/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Eventi

Industria

Mercato del lavoro

Web e Social Network

Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026

Fonte

Merck & Co., Inc.

Emittente

1.00

0

30/09/2026

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Fonte

Merck & Co., Inc.

Emittente

1.00

0

28/09/2026

Mercato del lavoro

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor

Fonte

Merck & Co., Inc.

Emittente

1.00

0

25/09/2026

Industria

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Fonte

Merck & Co., Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0